Interview with our CEO Evelina Vågesjö by the MedicineMaker

Therapeutic concepts, work and science being recognised for significant contributions in the advanced therapy pipeline in the MedicineMakers PowerList 2021.

  Clinical team publishes peer-reviewed expert opinion on how to optimise development of topical medicines, especially cell- and gene therapies

The team also published an expert opinion on the mechanism of actions explored and progress of pipeline in 2019 in Öhnstedt et al., Expert Opinion on Drug Discovery 2019;14(5):485-497.

  FirstWord Pharma shares news about CFO appointment and growth plans in Ilya Pharma

  First Word Pharma shares the news that Ilya Pharma was especially selected to Present ILP100 Accelerated Wound Healing Gene Therapy at US Military Health System Research Symposium (MHSRS) 2021

  New podcast with the co-founders of Ilya Pharma - moving quickly and efficiently forward and building a top notch team

  Science of the MOA and benefits of CXCL12 to accelerate healing highlighted in Nature Cardiology Reviews

The scientific findings of macrophages regulating blood flow in injured tissue and how CXCL12 is therapeutically facilitating this mechanism of action accelerating healing is highlighted by Nature Cardiology Reviews. Original article: Vågesjö, E. et al. Perivascular macrophages regulate blood flow following tissue damage. Circ. Res. https://doi.org/10.1161/CIRCRESAHA.120.318380 (2021)

  Blood flow regulating Macrophages, the science behind the scalable iLP-technology platform and lead candidate ILP100 published in Circulation Research

  Evelina Vågesjö CEO of Ilya Pharma included in the 2021 Power List in Advanced therapies by the Medicine Maker

Our CEO Evelina Vågesjö is listed for Advanced therapies by the TheMedicineMaker together with the former Head och Cell- and Genetherapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa.

  Coverage in BioProcess International of our recent clinical data and how we work with development and industrialisation of the ILP100 in topical and oral formulations to adress important unmet medical needs

  First in human data with ILP100-Topical picked up by Drug Discovery World - turning science into business

Extended data released by Ilya Pharma from the first in human trial WHILYAS-1.